Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06996756 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy for Alpha 1- Antitrypsin Deficiency
A Phase 1 study of Alpha-1 Antitrypsin Deficiency, sponsored by Weill Medical College of Cornell University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT06996756 is a Phase 1 study of Alpha-1 Antitrypsin Deficiency that is actively recruiting participants, run by Weill Medical College of Cornell University. The registered enrollment target is 16 participants, below the 3,077-participant average among 18 other Alpha-1 Antitrypsin Deficiency trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06996756, a Phase 1 study of Alpha-1 Antitrypsin Deficiency, is actively recruiting participants, sponsored by Weill Medical College of Cornell University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study of gene therapy to treat alpha 1-antitrypsin (AAT) deficiency. This study aims to treat AAT deficiency with a single administration of AAV8hAAT(AVL), a gene therapy that codes for an oxidation resistant form of the AAT protein, which if safe and if efficacious, will protect the lung on a persistent basis. We hope to learn the safety/toxicity and initial evidence of efficacy of intravenous delivery of this gene therapy to alpha 1-antitrypsin deficient individuals.
Conditions Studied
Interventions
- BIOLOGICAL AAV8hAAT(AVL)
Study Locations (1)
New York
- WCMC Department of Genetic Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2025-02-26 |
| Est. Completion | 2032-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06996756
The ClinicalTrials.gov registry entry for NCT06996756 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,077-participant average among 18 other Alpha-1 Antitrypsin Deficiency trials with a reported enrollment target (99% lower). The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alpha-1 Antitrypsin Deficiency appearing as the primary indexed condition, and to 1 intervention - of which AAV8hAAT(AVL) is the first listed.
NCT06996756 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06996756 about?
NCT06996756 is a clinical study titled "Gene Therapy for Alpha 1- Antitrypsin Deficiency". This is a study of gene therapy to treat alpha 1-antitrypsin (AAT) deficiency. This study aims to treat AAT deficiency with a single administration of AAV8hAAT(AVL), a gene therapy that codes for an oxidation resistant form of the AAT protein, which if safe and if efficacious, will protect the lung ...
What is the current status of trial NCT06996756?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2025-02-26. Estimated completion is 2032-08-01.
What conditions does trial NCT06996756 study?
This clinical trial studies the following conditions: Alpha-1 Antitrypsin Deficiency.
What interventions are being tested in trial NCT06996756?
The interventions under investigation include: AAV8hAAT(AVL) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06996756?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06996756 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alpha-1 Antitrypsin Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)
RECRUITING · Phase 1
-
Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants
RECRUITING · Phase 1
-
A Phase 1, First-in-human Study of VX-668
COMPLETED · Phase 1
-
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
RECRUITING
-
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.